Home › NCT04883905

ELEVATE, a Registry of Patients With Acute Hepatic Porphyria (AHP)

ELEVATE, a Global Observational Longitudinal Prospective Registry of Patients With Acute Hepatic Porphyria (AHP)

Who can join

Ages 12 and older · All sexes

Inclusion Criteria:

* Documented diagnosis of AHP, per physician's determination

Exclusion Criteria:

* Currently enrolled in a clinical trial for any investigational agent

About the study

This global patient registry is being conducted to characterize the natural history and real-world clinical management of patients with AHP, and to further characterize the real-world safety and effectiveness of givosiran and other approved AHP therapies.

Sponsor: Alnylam Pharmaceuticals · Participants: 150 · Started: Apr 26, 2021

Contact the study team

• Alnylam Clinical Trial Information Line · Phone: 1-877-ALNYLAM
• Alnylam Clinical Trial Information Line · Phone: 1-877-256-9526

Official record on ClinicalTrials.gov — NCT04883905

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.